#akynzeo | Explore Tumblr posts and blogs

ciaossu-imagines · 19 days ago

Note

❄️ from end of the year ask game <3

What was the highlight of your year?

I don’t feel like 2024 was really my year. There wasn’t a lot of stand out moments that are automatically coming to mind. I’m trying hard to focus on all the positives about it, but no big moments in particular are popping out, though that could be just my brain.

Martha, Nix, Cathy, Lou, and Butter have all really made my year better through their messages and friendship. I’ve been a really horrible friend in a lot of ways, since I’m struggling with answering messages quickly, but just know you were loved.

There were so many great fanfics and fanfic writers that have made my year better. I really hope, next year, to start being better about commenting, reblogging, and letting them know how much their fics mean to me or their works or their ideas.

I discovered a new author I really love this year in the horror genre, so that was great, and I fell in love with many new fandoms this year, so I have a lot of thanks to give to those professional writers.

I had a lot of absolutely fantastic commissoners this year and had the honour of working on a lot of amazing things because of them and they all have my utmost respect and love.

I got to slip more into my role and grow in my professional career in real life. Pharmacy is a lot more than people think and I have the opportunity to learn something new each and every day in my job or to do something good for people each and every day. Today, I managed to get compassionate care to cover the full cost of someone’s much needed Akynzeo, which he’d been paying several hundred dollars out of pocket for up until that point. For those who don’t recognize the brand name, it’s used for chemotherapy-induced nausea and vomiting. It still astounds me that this man had had to pay, while going through cancer, all this money, only adding more stress to him and I’m so glad that we were able to get that done for him.

I went through a whole ‘nother year of therapy and I worked hard, pushing myself to my limits, tearing down walls brick by brick to try to get myself better and learn coping skills and mechanisms. I volunteer my time for several mental-health causes and that actually made my life better…I regret stopping but I just no longer had the time.

#replies #admin chatter

2 notes · View notes

biotech-news-feed · 28 days ago

Link

Opinion/decision on a Paediatric investigation plan (PIP): Akynzeo, Fosnetupitant,Palonosetron, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0418/2023 #BioTech #science

#Blockchain #Crypto

0 notes

ptmasterguide · 2 years ago

Text

AKYNZEO and Warfarin

In this article, we will discuss AKYNZEO and Warfarin. So, let’s get started. Although it was predicted that co-administration of intravenous AKYNZEO with warfarin would not substantially increase the systemic exposure to S-warfarin (CYP2C9 substrate), the activeenantiomer, the effects of AKYNZEO for injection and AKYNZEO capsules on INR andprothrombin time have not been studied. Monitor INR and…

View On WordPress

#AKYNZEO #Anticancer Drugs #Medicine #Oncology #Pharmacology #Physiotherapy

0 notes

brightoredsmoker · 3 years ago

Text

Say it…and now pay the fag tax.

https://paypal.me/akynzeo?country.x=GB&locale.x=en_GB

120 notes · View notes

mate1959 · 3 years ago

Text

2021-08-23 Chemo

Heute war es also soweit. Der Tag begann wunderschön mit einem Sonnenaufgang in einem tiefen Morgenrot und wunderschönen Wolkenformationen. Der Weg zur Ärztin war trotzdem gefühlsmässig wie damals, als ich als Kind zum Zahnarzt musste in Erwartung von Bohrer und Schmerzen. Zum Glück ist es danach vorbei. So ist es auch heute.

Zuerst hatte ich ein Gespräch mit Frau Jermann. Viel Neues gab es nicht zu berichten. Ich erzählte ihr, wie es mir die letzten zwei Wochen so ergangen ist. Und da es keine dramatischen Entwicklungen gab, war das schnell abgehakt. Im Moment passiert ja vieles in meinem Körper drin. Draussen können meine Lieben und kann ich unterstützend wirken und Einfluss nehmen.

Von der Krankenversicherung hat Frau Jermann seit ihrer Anfrage wegen der Immuntherapie nichts gehört. Das erstaunt sie doch sehr. Sie wird nachhaken und die Dringlichkeit einer Entscheidung betonen. Wir unsererseits haben beschlossen, die Immuntherapie auf jeden Fall durchzuführen und notfalls auch selber zu bezahlen. Ich erhielt mehrere Inputs von verschiedenen Seiten, diese Therapie unterstützend zur Chemotherapie zu machen. Die Ärztin bestellt diese nun und am Mittwoch habe ich einen ersten Termin dafür.

Danach ging es auf den Coiffeur-Sessel und die Zeremonie begann. Zuerst gab es Akynzeo, das habe ich das letzte Mal in meiner Aufzählung vergessen. Akinzeo ist ein Antiemetikum.

(Erklärungen am Ende des Textes)

Dann wurde wieder die Nadel in die Vene gesteckt und zuerst eine Kochsalzlösung eingelassen. Danach Cortison gegen die Übelkeit. Das wird mich vielleicht wieder in ein Hoch versetzten. Anschliessend gab es die eigentliche Chemo mit den Zytostatika.

Danach war es vorbei und es gab in der nahe gelegenen Pizzeria ein Pizza mit Estela, die mich auch dieses Mal liebevoll begleitet hat. Die nächsten Tage geht es nun weiter mit den begleitenden Medikamenten gegen Übelkeit, Magenschutz etc.

Einen Schrecken eingejagt hat mir mein lieber Freund Andi, der einen Badeunfall erlitten und sich dabei einen Halswirbel gebrochen hat. Das professionelle Vorgehen des Bademeisters hat ihn vor Schlimmeren wie den Rollstuhl oder den Tod bewahrt. So ist er mit dem Schrecken, Schmerzen und einer Halsstütze für die nächsten drei Monate davongekommen. Gute Besserung Andi. Und wieder einmal der Weckruf, dass es, bei aller Sicherheit in unserer Gesellschaft schnell und dramatisch anders sein kann.

So. Bitte entschuldigt diesen nüchtern vorgetragenen Bericht. Die ersten Nebenwirkungen sind schnell aufgetreten heute. Schwindelgefühle. Zum Glück ist mir nicht schlecht. Und ich habe die nächste Raketenstufe auf dem Weg zum gesund sein gezündet.

So today was the day. The day started beautifully with a sunrise in a deep morning red and beautiful cloud formations. The way to the doctor was nevertheless feeling like when I had to go to the dentist as a child in anticipation of drills and pain. Fortunately, it is over after that. It is the same today.

First I had a conversation with Mrs. Jermann. There was not much new to report. I told her how I had been for the last two weeks. And since there were no dramatic developments, that was quickly ticked off. At the moment, a lot is happening inside my body. Outside, my loved ones and I can be supportive and have an influence.

Mrs. Jermann has not heard anything from the health insurance company since her inquiry about the immunotherapy. She is very surprised about that. She will follow up and emphasize the urgency of a decision. For our part, we have decided to carry out the immunotherapy in any case and, if necessary, to pay for it ourselves. I received several inputs from different sides to do this therapy in addition to the chemotherapy. The doctor is now ordering it and on Wednesday I have a first appointment for it.

After that I went to the hairdresser's chair and the ceremony began. First there was Akynzeo, I forgot that last time in my list. Akinzeo is an antiemetic. (Explanations at the end of the text).

Then again the needle was put into the vein and first a saline solution was let in. Then cortisone for the nausea. This might put me back on a high. Then there was the actual chemo with the cytostatics.

After that it was over and I had a pizza in the nearby pizzeria with Estela, who also lovingly accompanied me this time. The next few days I will continue with the accompanying medications against nausea, stomach protection etc.

My dear friend Andi gave me a fright when he had a swimming accident and broke a neck vertebra. The professional approach of the lifeguard saved him from worse like the wheelchair or death. So he got away with the scare, pain and a neck brace for the next three months. Get well soon Andi. And once again the wake-up call that, for all the safety in our society, things can change quickly and dramatically.

So. Please excuse this soberly presented report. The first side effects appeared quickly today. Dizziness. Fortunately, I don't feel nauseous. And I have ignited the next rocket stage on the way to being healthy.

Así que hoy era el día. El día comenzó maravillosamente con un amanecer en un rojo intenso de la mañana y hermosas formaciones de nubes. Sin embargo, el camino al médico fue emocionalmente como cuando tenía que ir al dentista de niño, anticipando los taladros y el dolor. Afortunadamente, después de eso se acaba. Lo mismo ocurre hoy en día.

Primero tuve una conversación con la señora Jermann. No hay muchas novedades. Le conté cómo había estado las últimas dos semanas. Y como no hubo acontecimientos dramáticos, eso quedó rápidamente atrás. En este momento, están pasando muchas cosas dentro de mi cuerpo. En el exterior, mis seres queridos y yo podemos ser un apoyo y una influencia.

La Sra. Jermann no ha tenido noticias de la compañía de seguros de salud desde que preguntó por la inmunoterapia. Está muy sorprendida por ello. Hará un seguimiento y hará hincapié en la urgencia de una decisión. Por nuestra parte, hemos decidido llevar a cabo la inmunoterapia en cualquier caso y, si es necesario, pagarla nosotros mismos. Recibí varias aportaciones de diferentes partes para hacer esta terapia como apoyo a la quimioterapia. El médico lo está pidiendo ahora y tengo una primera cita para ello el miércoles.

Luego me dirigí a la silla del peluquero y comenzó la ceremonia. Primero fue Akynzeo, lo olvidé la última vez en mi lista. Akinzeo es un antiemético. (Explicaciones al final del texto)

A continuación, se volvió a introducir la aguja en la vena y se dejó entrar primero una solución salina. Luego cortisona contra las náuseas. Eso podría volver a ponerme en un aprieto. Luego vino la quimioterapia propiamente dicha con los citostáticos.

Después se acabó y comí una pizza en la pizzería cercana con Estela, que también me acompañó cariñosamente esta vez. Los próximos días continuaré con los medicamentos de acompañamiento contra las náuseas, la protección del estómago, etc.

Mi querido amigo Andi me dio un susto cuando tuvo un accidente de natación y se rompió una vértebra del cuello. La profesionalidad del socorrista le salvó de cosas peores, como una silla de ruedas o la muerte. Así que se escapó con un susto, dolor y un collarín durante los siguientes tres meses. Recupérate pronto Andi. Y una vez más la llamada de atención de que, con toda la seguridad de nuestra sociedad, las cosas pueden cambiar rápida y dramáticamente.

Así que, por favor, disculpen este informe sobriamente presentado. Los primeros efectos secundarios aparecieron rápidamente hoy. Mareos. Afortunadamente, no me siento mal. Y he encendido la siguiente etapa del cohete en el camino hacia la salud.

_____________________________________________________________

Antiemetika sind Wirkstoffe, die für die Vorbeugung und Behandlung von Übelkeit und Erbrechen unterschiedlicher Ursache eingesetzt werden. Zum Beispiel bei einer Reisekrankheit, einer Migräne, einer Magen-Darm-Grippe, bei einer Chemotherapie und nach Operationen. Ihre Effekte beruhen auf dem Antagonismus an verschiedenen Neurotransmitter-Rezeptoren.

Akinzeo – Struktur und Eigenschaften Netupitant (C30H32F6N4O, Mr = 578.6 g/mol) ist ein fluoriertes Piperazin- und Pyrimidin-Derivat. Palonosetron (C19H24N2O, Mr = 296.4 g/mol) liegt in Arzneimitteln als Palonosetronhydrochlorid vor, ein weisses, kristallines Pulver, das in Wasser löslich ist.

(Quelle: Pharmawiki) __________________________ Antiemetics are active ingredients used for the prevention and treatment of nausea and vomiting of various causes. For example, in motion sickness, migraine, gastrointestinal flu, chemotherapy and after surgery. Their effects are based on antagonism at various neurotransmitter receptors.

Akinzeo - structure and properties Netupitant (C30H32F6N4O, Mr = 578.6 g/mol) is a fluorinated piperazine and pyrimidine derivative. Palonosetron (C19H24N2O, Mr = 296.4 g/mol) is present in drugs as palonosetron hydrochloride, a white crystalline powder that is soluble in water.

(Source: Pharmawiki) ___________________________

Los antieméticos son sustancias activas que se utilizan para la prevención y el tratamiento de las náuseas y los vómitos por diversas causas. Por ejemplo, para el mareo, la migraña, la gripe gastrointestinal, la quimioterapia y después de la cirugía. Sus efectos se basan en el antagonismo en varios receptores de neurotransmisores.

Akinzeo - estructura y propiedades El Netupitant (C30H32F6N4O, Mr = 578,6 g/mol) es un derivado fluorado de la piperazina y la pirimidina. El palonosetrón (C19H24N2O, Mr = 296,4 g/mol) está presente en los medicamentos como clorhidrato de palonosetrón, un polvo cristalino blanco que es soluble en agua.

(Fuente: Pharmawiki)

1 note · View note

recetraro · 7 years ago

Photo

https://www.oncologiabrasil.com.br/anvisa-aprova-akynzeo-netupitanto-palonosetrona-para-prevencao-de-nauseas-e-vomitos-em-pacientes-que-estao-passando-por-quimioterapia/ #oncologia #oncology #clinicaloncology #oncologiabrasil #supportivecare #palliativecare #pallionc #cuidadospaliativos #cuidadosdesuporte #nepa #akynzeo #mundipharma (em São Paulo, Brazil)

#pallionc #oncology #supportivecare #palliativecare #akynzeo #oncologia #cuidadosdesuporte #mundipharma #oncologiabrasil #clinicaloncology #cuidadospaliativos #nepa

0 notes

bearni · 3 years ago

Text

Global Chemotherapy Induced Nausea And Vomiting (CINV) Drugs Market By Type (Aloxi,Zofran Generic,Kytril Generic,Emend,Akynzeo,SUSTOL,Rolapitant), By Application (Acute CINVDelayed CINV), By Country, And Manufacture – Industry Segment, Competition Scenario And Forecast By 2029

Industry analysis and future outlook on Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Global Market brings a systematic perspective of the market execution and assists in strategic decision making for worldwide and additionally the regional situation. Detailed sections provides in-depth arrangement, the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs contemplate that make sense of different perspectives relating to the global market. To begin with, the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market definition, applications, arrangement, and industry esteem chain structure are incorporated into the answer, to target gathering of people on restricting Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market elements including drivers, limitations, openings, patterns, applications, topographical/local Chemotherapy Induced Nausea and Vomiting (CINV) Drugs markets, and aggressive scene.

Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Industry Market was valued at USD XX Million in the year 2020. The market is further estimated to grow at a CAGR of XX% from 2020 to reach USD XX Million by the year 2029.

Get Quick Free Sample Brochure report at: https://www.globalresearchview.com/report/global-chemotherapy-induced-nausea-and-v/GRV55372/request-sample/

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market rivalry by top makers/players, with Chemotherapy Induced Nausea and Vomiting (CINV) Drugs deals volume, Value (USD/Unit), Revenue (Mn/Bn USD) and market size for every producer/player; the significant players include:

GlaxoSmithKline Helsinn Heron Therapeutics Merck Tesaro

Worldwide Chemotherapy Induced Nausea and Vomiting (CINV) Drugs statistical surveying report uncovers that the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs business will develop with pivotal CAGR over the estimated forecast period of 2021 and 2029. The global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market in forecast years 2021-2029, is expected to hit Mn/Bn$ XX USD by 2029. The Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market gives broad development openings over the both created and creating economies. Further, the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs business sectors could profit without a doubt from the expanding interest to bring down Chemotherapy Induced Nausea and Vomiting (CINV) Drugs expenses of treatment over the globe.

Inquiry for Buying report to get customization at: https://www.globalresearchview.com/report/global-chemotherapy-induced-nausea-and-v/GRV55372/inquiry

Key Highlights of the Report:

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Report provides forecast and industry outlook for the period of 2021-2029 with 2020 as the base year and covering historic data for years 2015-2019.

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market outlook with Porter’s 5 Forces Analysis will provide market dynamics (Drivers, Restraints, Opportunities & Threats).

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Competitive landscape section gives you the competitive edge over other key players in the market (Key Business Strategies, Recent Development M&A, Company Overview, Products/Services Portfolio & Financial Overview).

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Technological Scenarios & Expected Developments.

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs End-Use Industry & Consumer Behaviour Trends.

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Export-Import Scenario.

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Regulatory Policies across each region.

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs In-depth analysis on Industry Trends & Dynamics across each segment covered in the report.

Based on Type, Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market report shows development rate of each type, covers:

Aloxi Zofran Generic Kytril Generic Emend Akynzeo SUSTOL Rolapitant

End clients/applications, Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market report centers around the status and viewpoint for best applications/end clients, development rate for every application, this can be isolated into:

Acute CINV Delayed CINV

Access More Information at: https://www.globalresearchview.com/report/global-chemotherapy-induced-nausea-and-v/GRV55372

In conclusion, the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs industry report unveils research finding, outcomes, conclusions. Likewise, disclose various Chemotherapy Induced Nausea and Vomiting (CINV) Drugs data sources, traders/vendors, suppliers, manufacturers, sales channel, and addendum. In short, the overall Chemotherapy Induced Nausea and Vomiting (CINV) Drugs report is a lucrative document for people implicated in Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market.

Global Impact of COVID-19 Analysis:

COVID19 is an unrivaled global public health emergency that affects almost every industry, so the projected long-term impact will affect industry growth over the forecast period. The report provides insights into COVID19, taking into account changes in consumer behavior and demand, purchasing behavior, supply chain diversion, the dynamics of current market forces, and significant government intervention. Insights, analysis, estimates and forecasts considering the impact of COVID19 on the market.

About Us:

GlobalResearchView (GRV) is one of the leading market research company which aims to serve the most excellent research to the various sectors of business. We are prominent in satisfying all kinds of market research needs.

Jennifer Da (Head Global Business Development) – Global Research View(GRV) 701, Milton Avenue, East Ham,London. United kingdom. Pincode – 4E6 1BN Email: [email protected] Websites: www.globalresearchview.com Tel: +44 020 8638 7098

#Global Chemotherapy Induced Nausea And Vomiting (CINV) Drugs Market World Chemotherapy Induced Nausea And Vomiting (CINV) Drugs Market Europ

0 notes

vivekbajaj-grs · 3 years ago

Text

Global Chemotherapy-Induced Nausea and Vomiting Drugs Sales Market Report 2021

The global Chemotherapy-Induced Nausea and Vomiting Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chemotherapy-Induced Nausea and Vomiting Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type

Download FREE Sample of this Report @ https://www.grandresearchstore.com/report-sample/global-chemotherapyinduced-nausea-vomiting-drugs-2021-715

Existing Drugs

Akynzeo (Netupitant-Palonosetron FDC)

Aloxi (Palonosetron)

Emend (Aprepitant)

Kytril Generic (Granisetron)

Zofran Generic (Ondansetron)

Pipeline Drugs

SUSTOL (Granisetron Injection extended release)

Rolapitant

Segment by Application

Serotonin Receptor Antagonists

NK1 Receptor Antagonists

The Chemotherapy-Induced Nausea and Vomiting Drugs market is analysed and market size information is provided by regions (countries). Segment by Application, the Chemotherapy-Induced Nausea and Vomiting Drugs market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company

Merck & Co., Inc.

GlaxoSmithKline plc

Tesaro, Inc.

Helsinn Group

F. Hoffmann-La Roche Ltd.

Heron Therapeutics, Inc.

Dr. Reddy's Laboratories Ltd.

Acacia Pharma

Sun Pharmaceutical Industry Ltd.

Otsuka Holdings Co., Ltd.

Get the Complete Report & TOC @ https://www.grandresearchstore.com/life-sciences/global-chemotherapyinduced-nausea-vomiting-drugs-2021-715

Table of content

1 Chemotherapy-Induced Nausea and Vomiting Drugs Market Overview 1.1 Chemotherapy-Induced Nausea and Vomiting Drugs Product Scope 1.2 Chemotherapy-Induced Nausea and Vomiting Drugs Segment by Type 1.2.1 Global Chemotherapy-Induced Nausea and Vomiting Drugs Sales by Type (2016 & 2021 & 2027) 1.2.2 Existing Drugs 1.2.3 Akynzeo (Netupitant-Palonosetron FDC) 1.2.4 Aloxi (Palonosetron) 1.2.5 Emend (Aprepitant) 1.2.6 Kytril Generic (Granisetron) 1.2.7 Zofran Generic (Ondansetron) 1.2.8 Pipeline Drugs 1.2.9 SUSTOL (Granisetron Injection extended release) 1.2.10 Rolapitant 1.3 Chemotherapy-Induced Nausea and Vomiting Drugs Segment by Application 1.3.1 Global Chemotherapy-Induced Nausea and Vomiting Drugs Sales Comparison by Application (2016 & 2021 & 2027) 1.3.2 Serotonin Receptor Antagonists 1.3.3 NK1 Receptor Antagonists 1.4 Chemotherapy-Induced Nausea and Vomiting Drugs Market Estimates and Forecasts (2016-2027) 1.4.1 Global Chemotherapy-Induced Nausea and Vomiting Drugs Market Size in Value Growth Rate (2016-2027) 1.4.2 Global Chemotherapy-Induced Nausea and Vomiting Drugs Market Size in Volume Growth Rate (2016-2027) 1.4.3 Global Chemotherapy-Induced Nausea and Vomiting Drugs Price Trends (2016-2027) 2 Chemotherapy-Induced Nausea and Vomiting Drugs Estimates and Forecasts by Region 2.1 Global Chemotherapy-Indu

CONTACT US: 276 5th Avenue, New York , NY 10001,United States International: (+1) 646 781 7170 / +91 8087042414 Email: [email protected] Follow Us On linkedin :- https://www.linkedin.com/company/grand-research-store/

#Chemotherapy-Induced Nausea and Vomiting Drugs

0 notes

marketanalysisdata · 4 years ago

Text

Gastrointestinal Therapeutics Market Size, Share, Research and Competitive Landscape 2025

7th May 2021 – Global Gastrointestinal Therapeutics Market is anticipated to reach USD 65.1 billion by 2025. The market is anticipated to rise at a healthy growth rate in the years to come. Gastrointestinal disorders are medical situations associated with the digestive system that disturb the small & large intestine, colon, and rectum. The syndromes mostly comprise peptic ulcer diseases, irritable bowel syndrome and constipation, categorized by several symptoms and signs such as bloating, pain, diarrhea, vomiting, and nausea. Gastrointestinal therapeutics comprises medications, which are commercially accessible in the market namely Afinitor, Aciphex, Akynzeo, Prilosec and Dificid.

In addition, the factors that propel the growth of market comprise the growing healthcare spending, increasing geriatric population, rising prevalence of gastrointestinal disease due to additional numbers of clinical trials, unhealthy dietary habits. On the other hand, the high competition among several key players to lead the market may ultimately rule the price attrition, and hamper the growth of market. However, this Gastro intestinal therapeutics has side effects, such as they have a low diagnosis rates, and stern rules for the approval of drugs. These factors will limit the growth of market in the years to come. The market is anticipated to grow at a significant CAGR of 6.6% in the upcoming period as the scope, product types and its applications are increasing across the globe.

Access Gastrointestinal Therapeutics Market Report with TOC @ https://www.millioninsights.com/industry-reports/gastrointestinal-therapeutics-market

Gastrointestinal Therapeutics industry may be explored by type, Route Administration, applications, Distribution Channel and geography. The market may be explored by type as Branded, (Antacids, Enzyme Replacement Therapies, Amino salicylates, Proton Pump Inhibitors, H2 Antagonists, Laxatives, Antiemetics, Biologics, Antidiarrheals, others), Generics. Branded gastrointestinal drugs dominated the market in 2016. However, it is anticipated to observe a decline in CAGR during the upcoming period due to saturation of generic medicines in the market. Gastrointestinal Therapeutics Market may be explored by Route Administration as Intravenous, Oral, and Others. “Intravenous” segment dominated the route administration in the industry in 2016. Gastrointestinal Therapeutics industry may be explored by applications as GERD, Ulcerative Colitis, Crohn’s Disease, and others. “Others” segment dominated the market in 2016. This “others” segment may comprise chronic idiopathic constipation, irritable bowel syndrome opioid-induced constipation, diarrhea, nausea, recurrent gastrointestinal infections, gastrointestinal stromal tumor, and pancreatic insufficiency.

Gastrointestinal Therapeutics Market may be explored by Distribution Channel as Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies. The Online pharmacies segment dominated the Gastrointestinal Therapeutics industry in 2017. In addition, growing incidence of chronic diseases has caused in an extensive gap in the source of and demand for main drugs. The factors are anticipated to present remunerative development projections for online pharmacies throughout the upcoming period.

North America accounted for the major share of the global Gastrointestinal Therapeutics Market Size Analysis in 2016 and will continue to rule the roost in the forecast period. The market for Gastrointestinal Therapeutics in North America, especially in the U.S., is the most lucrative one and gaining robust traction from numerous features such as changing lifestyle, resultant in grater occurrence of gastrointestinal diseases will upsurge the gastrointestinal therapeutics in North America region in the years to come. North America followed by Asia-Pacific region.

Some of the key players that fuel the growth of the gastrointestinal therapeutics industry include Johnson & Johnson, Abbott Laboratories, AbbVie Inc., Salix Pharmaceuticals, Pfizer Inc, AstraZeneca, Takeda Pharmaceutical Company Limited, Astellas Pharma US, Inc., ALLERGAN, and GlaxoSmithKline Plc. The leading companies are taking up partnerships, mergers and acquisitions, and joint ventures in order to boost the inorganic growth of the industry.

Request a Sample Copy of Gastrointestinal Therapeutics Market Report @ https://www.millioninsights.com/industry-reports/gastrointestinal-therapeutics-market/request-sample

0 notes

latestmarketresearchtrends-blog · 4 years ago

Text

Gastrointestinal Therapeutics Market Analysis by Key Players, Industry Growth, Sales Forecast and Supply Demand to 2025

Access Gastrointestinal Therapeutics Market Report with TOC @ https://www.millioninsights.com/industry-reports/gastrointestinal-therapeutics-market

Request a Sample Copy of Gastrointestinal Therapeutics Market Report @ https://www.millioninsights.com/industry-reports/gastrointestinal-therapeutics-market/request-sample

0 notes

ptmasterguide · 2 years ago

Text

AKYNZEO and Hypersensitivity

In this article, we will discuss AKYNZEO and Hypersensitivity. So, let’s get started. Hypersensitivity Hypersensitivity reactions, including anaphylaxis, have been reported in patients treated with palonosetron, one of the components of AKYNZEO, with or without known hypersensitivity to other 5-HT3 receptor antagonists.

View On WordPress

#AKYNZEO #Anticancer Drugs #Medicine #Oncology #Pharmacology #Physiotherapy

0 notes

statzyreportsmarketresearch · 4 years ago

Text

Global Chemotherapy-Induced Nausea and Vomiting Drugs Market

The report forecast global Chemotherapy-Induced Nausea and Vomiting Drugs market to grow to reach xxx Million USD in 2019 with a CAGR of xx% during the period 2020-2025 due to coronavirus situation. The report offers detailed coverage of Chemotherapy-Induced Nausea and Vomiting Drugs industry and main market trends with impact of coronavirus. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Chemotherapy-Induced Nausea and Vomiting Drugs by geography. The report splits the market size, by volume and value, on the basis of application type and geography. First, this report covers the present status and the future prospects of the global Chemotherapy-Induced Nausea and Vomiting Drugs market for 2015-2024. And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru]. At the same time, we classify Chemotherapy-Induced Nausea and Vomiting Drugs according to the type, application by geography. More importantly, the report includes major countries market based on the type and application. Finally, the report provides detailed profile and data information analysis of leading Chemotherapy-Induced Nausea and Vomiting Drugs company.

Key Content of Chapters as follows (Including and can be customized) : Part 1: Market Overview, Development, and Segment by Type, Application & Region Part 2: Company information, Sales, Cost, Margin etc. Part 3: Global Market by company, Type, Application & Geography Part 4: Asia-Pacific Market by Type, Application & Geography Part 5: Europe Market by Type, Application & Geography Part 6: North America Market by Type, Application & Geography Part 7: South America Market by Type, Application & Geography Part 8: Middle East & Africa Market by Type, Application & Geography Part 9: Market Features Part 10: Investment Opportunity Part 11: Conclusion

Market Segment as follows: By Region Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia] Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland] North America[United States, Canada, Mexico] Middle East & Africa[GCC, North Africa, South Africa] South America[Brazil, Argentina, Columbia, Chile, Peru] Key Companies Merck & Co., Inc. GlaxoSmithKline plc Tesaro, Inc. Helsinn Group F. Hoffmann-La Roche Ltd. Heron Therapeutics, Inc. Dr. Reddy's Laboratories Ltd. Acacia Pharma Sun Pharmaceutical Industry Ltd. Otsuka Holdings Co., Ltd. Market by Type Existing Drugs Akynzeo (Netupitant-Palonosetron FDC) Aloxi (Palonosetron) Emend (Aprepitant) Kytril Generic (Granisetron) Zofran Generic (Ondansetron) Pipeline Drugs SUSTOL (Granisetron Injection extended release) Rolapitant Market by Application Serotonin Receptor Antagonists NK1 Receptor Antagonists

for free sample report please visit : https://www.statzyreports.com/report.php?reportname=SR150721

PHONE NUMBER (IN)- +8484035727 (US)- +12094187979

EMAIL ADDRESS

EMAIL:[email protected] EMAIL:[email protected]

#Global Chemotherapy-Induced Nausea and Vomiting Drugs

0 notes

poojakumari · 4 years ago

Text

CHEMO NAUSEA

Table of content

Overview

Why chemotherapy makes you sick?

Dependent factors for chemo nausea and vomiting

How to manage nausea?

Drugs to manage chemo nausea

Conclusion

OVERVIEW

Since 1950s doctors have been using chemotherapy to treat cancer which kills the cancer cells throughout the body with the help of drugs. One drawback of this treatment is Nausea and vomiting. In the past people used to live with these side effects but this is not the case anymore. There are many drugs and remedies to get rid of this chemo nausea or vomiting. There are also several ways through which you can prevent the nausea and vomiting after chemotherapy.

WHY CHEMOTHERAPY MAKES YOU SICK?

Since the body sees the drugs as foreign, it sends a warning signal in your brain and digestive system. This triggers a switch in your brain which is vomiting centre of body. It throws outside the chemicals that creates the nausea feeling in your body. Another reason is, in some cases chemo can cause harm to your digestive system which may also lead you to nausea and vomiting.

Chemotherapy can cause three types of nausea and vomiting as follows:-

· ACUTE – It starts within few hours of the treatment.

· DELAYED – It starts after 24 hours of the treatment and can last for a few days.

· ANTICIPATORY – It starts even before you get the treatment since you expect to feel sick.

DEPENDENT FACTORS FOR CHEMO NAUSEA AND VOMITING

How likely you are to get affected by chemo nausea vomiting depends on several things such as:-

· Type of the treatment used: The drugs that you are being given during your treatment are more likely to cause nausea and vomiting than treatment that affects only one area of your body such as radiation therapy.

· When or how often drugs are given: Time gap between the doses matters since if you are being given your 2nd dose in a very close time to 1st one, then your body have very less time to recover from the effects of 1st dose.

· Dose of drugs: Higher amount of chemo drugs are more likely to cause nausea and vomiting.

· Individual difference: Every person’s body reacts differently towards the medicines and hence responds in different way.

· Having tumor in liver, brain, gastrointestinal tract can increase the risk of nausea and vomiting.

· Some other drugs such as pain killers can make the nausea effect worsen.

Personal risk factors for chemo nausea and vomiting:-

· Being female

· Had chemo in the past

· Being younger

· Being very nervous and anxious

· Had Morning sickness at pregnancy period

· History of motion sickness

· Being prone to nausea and vomiting whenever you are sick.

. If you are a light drinker or non-drinker of alcohol

HOW TO MANAGE NAUSEA?

By following some tips you can prevent or manage nausea. Here are some suggestions which will help you to minimize your discomfort:-

· Eat small meals: Throughout the day try to have your meals in small part rather than large meal or eating fewer. Don’t skip your meals and also try to have some smaller meals few hours before the treatment to prevent nausea and vomiting.

· Food to avoid: It would be a best idea to avoid fatty, fried and sweet food. Foods that are cool like yogurt and ice-cream creates less bothersome during treatment.

· Avoid strong smells: Try to avoid strong smells which can trigger nausea and vomiting. When someone is cooking make a distance from kitchen and take fresh air to neutralize the smell.

· Have fluids/liquids in between meal: Cool beverages such as water, tea or ginger juice, unsweetened fruit juices which are well tolerated. 3MEDS, India’s best anti-cancer medicine supplier advises you to stay hydrated.

· Be comfortable: Take a rest after eating but it should not be for many hours and try to wear loose fitting clothes and distract yourself by doing other activities.

· Relaxation techniques: Meditation and deep breathing are considered very good way to relax your body.

· Use of ginger and peppermint: These are old age remedies, you can have a cup of ginger or peppermint tea. You can also inhale peppermint by putting few drops of it on a tissue and inhale it.

DRUGS TO PREVENT CHEMO NAUSEA

Doctors may prescribe you some medicines to have before or after your treatment which can help you to prevent/manage the chemo nausea and vomiting.

· Aprepitant (Emend)

· Dolasetron (Anzemet)

· Fosnetupitant / Palonosetron (Akynzeo)

· Granisetron (Kytril)

· Ondansetron (Zofren, Zuplenz)

· Palonosetron (Aloxi)

· Rolapitant (Varubi)

Take all the medicines on time for best results and try to have genuine quality medicines which you can very easily get on 3MEDS, best anti-cancer medicine provider and get your genuine medicines delivered at your door step.

CONCLUSION

There was a time when prevention or treatment measures for chemo nausea were not available but now it is very much possible so you don’t need to be worried. You can have medicines as well as prevention tips as given above to avoid and manage the feeling of nausea and vomiting after chemotherapy treatment. Try to not think about it before your treatment, keep yourself busy in other things to avoid the worsen effects. React positively to the change and be healthy.

0 notes

latestmarketreport · 5 years ago

Text

Gastrointestinal Therapeutics Market Future Trends, Outlook And Risk Factor By 2025

Felton - Gastrointestinal Therapeutics Market Report provides a complete analysis of the market. The Report focuses on manufacturers, suppliers, segmentation according to the application, major players, customers, opportunities, future roadmap, and furthermore. The competitive data type analysis includes capacity, market share, profit margin, market growth, consumer consumption, imports, exports, revenue, and etc. Marketing strategies, policies, industry chain that are changing the wave of the market are also catered in the report.

Global Gastrointestinal Therapeutics Market is anticipated to reach USD 65.1 billion by 2025. The market is anticipated to rise at a healthy growth rate in the years to come.

Request a PDF Sample @ https://www.millioninsights.com/industry-reports/gastrointestinal-therapeutics-market/request-sample

Gastrointestinal disorders are medical situations associated with the digestive system that disturb the small & large intestine, colon, and rectum. The syndromes mostly comprise peptic ulcer diseases, irritable bowel syndrome and constipation, categorized by several symptoms and signs such as bloating, pain, diarrhea, vomiting, and nausea. Gastrointestinal therapeutics comprises medications, which are commercially accessible in the market namely Afinitor, Aciphex, Akynzeo, Prilosec and Dificid.

In addition, the factors that propel the growth of market comprise the growing healthcare spending, increasing geriatric population, rising prevalence of gastrointestinal disease due to additional numbers of clinical trials, unhealthy dietary habits. On the other hand, the high competition among several key players to lead the market may ultimately rule the price attrition, and hamper the growth of market. However, these Gastro intestinal therapeutics have side effects, such as they have a low diagnosis rates, and stern rules for the approval of drugs. These factors will limit the growth of market in the years to come. The market is anticipated to grow at a significant CAGR of 6.6% in the upcoming period as the scope, product types and its applications are increasing across the globe.

Gastrointestinal Therapeutics Route of Administration Outlook (Revenue, USD Million, 2014 - 2025)

• Oral

• Intravenous

• Others

Gastrointestinal Therapeutics Application Outlook (Revenue, USD Million, 2014 - 2025)

• Ulcerative Colitis

• Crohn’s Disease

• GERD

• Others

Gastrointestinal Therapeutics Distribution Channel Outlook (Revenue, USD Million, 2014 - 2025)

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

Explore Full Report With Detailed TOC Here: https://www.millioninsights.com/industry-reports/gastrointestinal-therapeutics-market

Regional Analysis For Gastrointestinal Therapeutics Market:

For comprehensive understanding of market dynamics, the global Gastrointestinal Therapeutics Market is analyzed across key geographies namely: North America, Europe, Asia-Pacific, Latin America and Africa. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Significant Features that are under Offering and Key Highlights of the Reports:

– Detailed overview of Gastrointestinal Therapeutics Market

– Changing market dynamics of the industry

– In-depth market segmentation by Type, Application etc

– Historical, current and projected market size in terms of volume and value

– Recent industry trends and developments

– Competitive landscape of High-Performance Alloys Market

– Strategies of key players and product offerings

– Potential and niche segments/regions exhibiting promising growth.

Get in touch

At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

Contact Person:

Ryan Manuel

Research Support Specialist, USA

Email: [email protected]

Million Insights

Office No. 302, 3rd Floor, Manikchand Galleria,

Model Colony, Shivaji Nagar, Pune, MH, 411016 India

tel: 91-20-65300184

0 notes

pharmaphorumuk · 5 years ago

Text

Merck’s last-resort antibiotic Recarbrio nears EU approval

Merck & Co/MSD’s three-drug antibiotic Recarbrio has been recommended for approval in Europe for Gram-negative infections, but should be reserved for use in patients with limited treatment options.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) backed approval of Recarbrio at its meeting last week, a few months after the drug was approved by the FDA for complicated urinary tract and intra-abdominal infections (cIAI).

The new drug combines the active ingredients in MSD’s broad-spectrum antibiotic Primaxin (imipenem/cilastatin) with a new beta lactamase inhibitor called relebactam that is designed to restore susceptibility to imipenem in resistant strains.

Drugs in the carbapenem class like imipenem have become last-line treatments for a number of multidrug resistant (MDR) infections, so Recarbrio could offer a fallback option in people with serious infections.

The CHMP notes that Recarbrio should only be prescribed “after consultation with a physician with appropriate experience in the management of infectious diseases” and with consideration to “official guidance on the appropriate use of antibacterial agents.”

The drug targets Gram-negative pathogens like Enterobacter cloacea, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae and Pseudomonas aeruginosa.

Recarbrio’s reserved status means that it won’t be a big seller for MSD, with Cowen & Co analysts expecting sales to reach around $150 million in 2024, but it will be an important new option for patients.

The low returns on new antibiotic research have driven a lot of the multinational drugmakers out of the category, raising fears that MDR will become rampant and society could enter a post-antibiotic age where once-trivial infections can be life-threatening.

That disincentive is one of the factors behind a new UK proposal for a new payment system for antibiotics that will see companies paid upfront for access to new antibiotics based on their value to the NHS, rather than the volume of medicines sold.

Recarbrio was one of five new medicines recommended for approval by the CHMP at its latest meeting, along with Novartis’ wet age-related macular degeneration (AMD) therapy Beovu, Accord Healthcare’s generic versions of azacitidine for blood cancers and sedative dexmedetomidine, and Pfizer’s Amsparity – a biosimilar of AbbVie’s immunology blockbuster Humira (adalimumab).

There were also several new positive opinions on already-marketed drugs, including:

Janssen-Cilag’s Darzalex (daratumumab) for use in combination with Takeda’s Velcade (bortezomib), thalidomide and dexamethasone for adult patients with newly diagnosed multiple myeloma who are eligible for an autologous stem cell transplant;

A new 61 mg soft capsule formulation of Pfizer’s Vyndaqel (tafamidis) for the treatment of wild‑type or hereditary transthyretin amyloidosis in adult patients with transthyretin amyloid cardiomyopathy (ATTR-CM);

Extending the age-range for children with plaque psoriasis eligible for treatment with Janssen-Cilag’s Stelara (ustekinumab) to six years and over from 12 and over;

Extending the age range for treatment with Janssen-Cilag’s pulmonary multidrug‑resistant tuberculosis (MDR‑TB) therapy Sirturo (bedaquiline) to include adolescents aged over 12 as well as adults;

New oral and intravenous infusion formulations of Helsinn Birex Pharma’s Akynzeo (fosnetupitant/palonosetron) for prevention of chemotherapy-induced nausea and vomiting (CINV);

Eli Lilly’s Cyramza (ramucirumab) in combination with Roche’s Tarceva (erlotinib) for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating EGFR mutations;

A new film-coated formulation of Astellas’ Dificlir (fidaxomicin) that extends the use of the Clostridioides difficile infection (CDI) drug to include children weighing over 12.5 kg as well as adults.

The post Merck’s last-resort antibiotic Recarbrio nears EU approval appeared first on .

from https://pharmaphorum.com/news/mercks-last-resort-antibiotic-recarbrio-nears-eu-approval/

0 notes